- Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
-
Cheon YH, Kim MJ, Kang MG, Kim HJ, Lee SS, Kim CY, Jeon DH, Kim YE, Lee GW
- KMID: 1728007
- Yonsei Med J.
- 2011 Jul;52(4):695-698.
- doi: 10.3349/ymj.2011.52.4.695
Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous... -
- CITED
-
- Close
- SHARE
-
- Close
